{"id":214661,"title":"Archived 39: Summary of NACI statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T18:51:21.623000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines/summary-september-1-2022.html?wbdisable=false","snippet":"Archived 39: Summary of NACI statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines - Canada.ca Skip to main content Skip to \"About government\" We have archived this page and will not be updating it. You can use it for…","rawSnapshotUrl":"/api/snapshots/raw/214661","browseUrl":"https://replay.healtharchive.ca/job-1/20250418185121/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-bivalent-omicron-containing-mrna-covid-19-vaccines/summary-september-1-2022.html?wbdisable=false#ha_snapshot=214661","mimeType":"text/html","statusCode":200}